FibroGen’s Pamrevlumab Slows Lung Function Decline in IPF Patients, Trial Results Show

Idiopathic Pulmonary Fibrosis, News

Lung function decline in patients with idiopathic pulmonary fibrosis (IPF) was slowed by the investigational drug pamrevlumab, according to the results from a Phase 2b clinical trial. The results were presented ... Read more

March 15, 2016March 16, 2016

For IPF Patients, Results Appear Promising in Phase 2 Study from FibroGen’s Investigative Drug

Idiopathic Pulmonary Fibrosis, News

FibroGen recently announced the publication of results from a Phase 2 clinical trial (NCT01262001) in patients with idiopathic pulmonary fibrosis (IPF), testing a 48-week treatment with the company’s investigational drug FG-3019, ... Read more